TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2371073

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube placement in infants <2 kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Orogastric (OG) tube placement in infants <2 kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube placement in infants >2 kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Orogastric (OG) tube placement in infants >2 kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: No gastric intubation
Number of subjects: 39
Study: 350248

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (fast injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (slow injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other vasodilator hypotensive drugs
Number of subjects: 0
Study: 31593271

Group type: EXPERIMENTAL
Intervention: Hospital-initiated program combining transitional care and long-term self-management support (n=120)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (n=120)
Number of subjects: 240
Study: 27310606

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation therapy (6 sessions of 30 minutes each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 60
Study: 26362099

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 899
Study: 24111365

Group type: EXPERIMENTAL
Intervention: Self-directed home-based electrical muscle stimulation training (30 sessions, 1 hour each over 6 weeks)
Number of subjects: 16
Study: 20417976

Group type: EXPERIMENTAL
Intervention: Auro®
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cerumol®
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CleanEars®
Number of subjects: 38
Study: 18821171

Group type: EXPERIMENTAL
Intervention: Electronic echoendoscope
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mechanical echoendoscope
Number of subjects: 80
Study: 17910329

Group type: EXPERIMENTAL
Intervention: Recombinant 16-kDa protein (r16-kDa)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 38

Group type: COMPARATOR
Intervention: r16-kDa enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: ImmunoCAP (serum IgE measurement)
Number of subjects: 38
Study: 15583582

Group type: EXPERIMENTAL
Intervention: Oral administration of Polypodium leucotomos (PL) 7.5 mg/kg
Number of subjects: 9
Study: 11718591

Group type: EXPERIMENTAL
Intervention: Computer-tailored smoking cessation program
Number of subjects: 2934

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 2934
Study: 9164223

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1,250 mg/m2 as a 30‐minute intravenous infusion on days 1, 8, and 15 of each 28‐day cycle
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 on day 1) and Etoposide (80 mg/m2 on days 1, 2, and 3 of each 28‐day cycle)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cisplatin and Etoposide (EP)
Number of subjects: 53
Study: 7524907

Group type: EXPERIMENTAL
Intervention: G‐CSF (filgrastim 5 micrograms/kg/day) administered prior to and after PBSC reinjection
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no G‐CSF prior to leukaphereses or after high‐dose therapy)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (G‐CSF and control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 23
Study: 3109764

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (rt-PA) 80 mg (40 mg, 20 mg, and 20 mg in successive hours)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Intravenous streptokinase (SK) 1.5 million units over 1 hr
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (rt-PA)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Intravenous streptokinase (SK)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both rt-PA and SK
Number of subjects: 290
Study: 29072478

Group type: EXPERIMENTAL
Intervention: Higher levels of sensation seeking and perceived peer drinking
Number of subjects: 3287

Group type: EXPERIMENTAL
Intervention: Personality profiles of impulsivity, sensation seeking, and hopelessness
Number of subjects: 3287

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity
Number of subjects: 3287
Study: 28345121

Group type: EXPERIMENTAL
Intervention: In-person genomic counseling (intervention arm, n=98)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control (control arm, n=101)
Number of subjects: 199
Study: 26291080

Group type: EXPERIMENTAL
Intervention: 500 mg E-52862
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 600 mg E-52862
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 800 mg E-52862
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standardised meal
Number of subjects: 32
Study: 23756360

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) plus Tamoxifen
Number of subjects: 1445
Study: 20628233

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid infusions (monthly, bi-monthly, tri-monthly, or semestral)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 95
Study: 18641498

Group type: EXPERIMENTAL
Intervention: Sociograms used in focus group analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sociograms
Number of subjects: 0
Study: 16844628

Group type: EXPERIMENTAL
Intervention: ASCP with pressure control (group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: ASCP with flow control (group 2)
Number of subjects: 62
Study: 12728462

Group type: EXPERIMENTAL
Intervention: Iodine restriction (less than 100 micro g/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Iodine non-restriction
Number of subjects: 45
Study: 10915728

Group type: EXPERIMENTAL
Intervention: Interferon beta (6 million units, twice a week for 36 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No IFN therapy (control group)
Number of subjects: 20
Study: 8725871

Group type: EXPERIMENTAL
Intervention: Ergoset (1.6-2.4 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1483671

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg in saline solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg in saline solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 30
Study: 6198910

Group type: EXPERIMENTAL
Intervention: CAD/MOPP/ABV/radiotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MOPP/ABV plus dacarbazine (D)
Number of subjects: 71
Study: 31588504

Group type: EXPERIMENTAL
Intervention: >10% weight loss
Number of subjects: 10081

Group type: COMPARATOR
Intervention: Stable weight
Number of subjects: 10081
Study: 30473097

Group type: EXPERIMENTAL
Intervention: LY3298176 10 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: LY3298176 15 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: LY3298176 1.5 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: LY3298176 4.5 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Dulaglutide (DU)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 27225316

Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA‐rich fish oil capsules (800 mg/d DHA and 100 mg/d EPA)
Number of subjects: 706
Study: 24316517

Group type: EXPERIMENTAL
Intervention: Vancomycin 500 mg t.i.d. for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amoxicillin 500 mg t.i.d. for 7 days
Number of subjects: 20
Study: 22356596

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Supportive-experiential therapy (SET) group
Number of subjects: 245

Group type: COMPARATOR
Intervention: Educational level as a predictor
Number of subjects: 245
Study: 20504210

Group type: EXPERIMENTAL
Intervention: Rasagiline monotherapy
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Rasagiline therapy
Number of subjects: 398
Study: 18561718

Group type: EXPERIMENTAL
Intervention: 500 mg of ciprofloxacin given 24 hours before return
Number of subjects: 797

Group type: COMPARATOR
Intervention: Not applicable (group 1, no intervention)
Number of subjects: 797
Study: 15991508

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + 3 mg kg(‐1) lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (3 mg kg(‐1) lidocaine diluted with saline)
Number of subjects: 40
Study: 14602752

Group type: EXPERIMENTAL
Intervention: PTH (100 microg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11030676

Group type: EXPERIMENTAL
Intervention: Ultrasonography with Alvarado score
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control (clinical diagnosis)
Number of subjects: 302
Study: 8854194

Group type: EXPERIMENTAL
Intervention: ioversol
Number of subjects: 3854

Group type: COMPARATOR
Intervention: reference
Number of subjects: 3854
Study: 1468786

Group type: EXPERIMENTAL
Intervention: Health education program involving video workshops and contests on AIDS.
Number of subjects: 0
Study: 6541533

Group type: COMPARATOR
Intervention: High-dose dexamethasone (DXM) (regimen A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of DXM and high doses of metoclopramide (MCP) (regimen B)
Number of subjects: 24
Study: 31591408

Group type: EXPERIMENTAL
Intervention: Unenhanced CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced CT
Number of subjects: 0
Study: 30381011

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 144
Study: 27694568

Group type: EXPERIMENTAL
Intervention: Early food supplementation (608 kcal)
Number of subjects: 1667

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS)
Number of subjects: 1667

Group type: COMPARATOR
Intervention: 60 mg iron and 400 μg folic acid
Number of subjects: 1667
Study: 23867040

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation with mirror therapy (FES with MT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Functional electrical stimulation without mirror therapy (FES without MT)
Number of subjects: 23
Study: 22314470

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study: 21077775

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Hip Circumference (HC)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Number of subjects: 1642

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) and Hip Circumference (HC)
Number of subjects: 1642
Study: 18004207

Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11059968

Group type: EXPERIMENTAL
Intervention: Women with nonischemic CHF
Number of subjects: 199
Study: 9086977

Group type: EXPERIMENTAL
Intervention: Learned resourcefulness training (LRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 8443027

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 76
Study: 3529351

Group type: EXPERIMENTAL
Intervention: Sequential female sex hormones and/or 1,25(OH)2D3, 0.25 microgram per day
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 29352461

Group type: EXPERIMENTAL
Intervention: Probiotic L. reuteri lozenge (1 lozenge daily for 30 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mechanical therapy alone (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Probiotic L. reuteri lozenge
Number of subjects: 44
Study: 27197100

Group type: EXPERIMENTAL
Intervention: Standard polymeric diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 23
Study: 24323244

Group type: EXPERIMENTAL
Intervention: Physical activity behavioral intervention delivered via the Internet and one-on-one video chat sessions with a behavior-change coach.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control condition.
Number of subjects: 82
Study: 22189052

Group type: EXPERIMENTAL
Intervention: Naltrexone plus brief individual counseling
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 20724057

Group type: EXPERIMENTAL
Intervention: Simulation training (4‐h immersive simulation course in CPR leadership)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 18536619

Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT booster dose
Number of subjects: 358

Group type: COMPARATOR
Intervention: DTPa‐HBV‐IPV/Hib control
Number of subjects: 358
Study: 15452683

Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg/70 kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg/70 kg, intravenously administered)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12867520

Group type: EXPERIMENTAL
Intervention: Cognitively impaired patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitively unimpaired patients
Number of subjects: 0
Study: 10378917

Group type: EXPERIMENTAL
Intervention: Resistance training (RT; N = 14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CON; N = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (RT and CON)
Number of subjects: 21
Study: 10064355

Group type: EXPERIMENTAL
Intervention: Creatine phosphate-enriched cardioplegic solution (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cardioplegic solution (group II)
Number of subjects: 40
Study: 1838923

Group type: EXPERIMENTAL
Intervention: perindopril (ACE inhibitor)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 27859897

Group type: EXPERIMENTAL
Intervention: Health education and telephone counseling program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 102
Study: 25768849

Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/d (with possible adjustment to 40 mg/d)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Istradefylline 20 mg/d and 40 mg/d (previously taken in double-blind study)
Number of subjects: 308
Study: 24358296

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 100 and/or 200 micrograms/m(3) particulate matter
Number of subjects: 43

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 43
Study: 21221666

Group type: EXPERIMENTAL
Intervention: Cervical disc replacement (arthroplasty)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (fusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of adjacent segments between both groups
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clinical results for both groups
Number of subjects: 20
Study: 19478653

Group type: EXPERIMENTAL
Intervention: Intramuscular oxygen-ozone (O2O3) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simulated therapy (control)
Number of subjects: 60
Study: 18389665

Group type: EXPERIMENTAL
Intervention: Non-activated autologous platelet-rich plasma (PRP) applied in 50 patients.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (50 patients) who underwent AAA EVAR without PRP.
Number of subjects: 100
Study: 16048250

Group type: EXPERIMENTAL
Intervention: Low glucose degradation product (GDP) dialysis solution
Number of subjects: 60
Study: 12199409

Group type: EXPERIMENTAL
Intervention: Listening practice with natural speech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening practice with DECtalk synthesized speech
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of natural speech and DECtalk synthesized speech
Number of subjects: 0
Study: 10073749

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg single dose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for at least 1 week)
Number of subjects: 150
Study: 7633860

Group type: EXPERIMENTAL
Intervention: Neonatal intensive care technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organized networks of neonatal intensive care units
Number of subjects: 0
Study: 2043179

Group type: EXPERIMENTAL
Intervention: Combination of quinine sulfate plus theophylline ethylene diamine (CTED)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CTED group (n = 34)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo group (n = 40)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Quinine group (n = 43)
Number of subjects: 164
Study: 6756775

Group type: EXPERIMENTAL
Intervention: PGE2 alone (Group A, 232 patients)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Prior intracervical laminaria insertion (Group B, 106 patients)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Laminaria and continuous intravenous oxytocin infusion (Group C, 62 patients)
Number of subjects: 400

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 400
Study: 31302802

Group type: EXPERIMENTAL
Intervention: Action and coping planning intervention (20-min session)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Assessment alone (Control)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Action and coping planning intervention
Number of subjects: 184
Study: 27784409

Group type: EXPERIMENTAL
Intervention: cb‐CBT‐I (computer-based cognitive behavioral therapy for insomnia)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sleep diary group (active control)
Number of subjects: 34
Study: 26459645

Group type: EXPERIMENTAL
Intervention: Metronome on
Number of subjects: 155

Group type: COMPARATOR
Intervention: Metronome off
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Metronome on (medical students)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Metronome off (medical students)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Metronome on (pediatric residents and fellows)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Metronome off (pediatric residents and fellows)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Metronome on (pediatric nurses)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Metronome off (pediatric nurses)
Number of subjects: 155
Study: 22889920

Group type: EXPERIMENTAL
Intervention: Fissure sealant with primer and bond (3M Scotchbond Multi‐Purpose Plus System primer and bond)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fissure sealant without primer and bond (Delton Plus)
Number of subjects: 78
Study: 21487863

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine injection
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine instillation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 68
Study: 19637428

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adefovir
Number of subjects: 0
Study: 17922738

Group type: EXPERIMENTAL
Intervention: Calcitriol therapy for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14994363

Group type: EXPERIMENTAL
Intervention: Warming therapy (heating vest set to medium heat for 3 hours a day for 21 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (heating vest set to off for 3 hours a day for 21 days)
Number of subjects: 21
Study: 11679149

Group type: EXPERIMENTAL
Intervention: HIV-1 MN rgp160 ImmunoAG vaccine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine)
Number of subjects: 22
Study: 9355055

Group type: EXPERIMENTAL
Intervention: Ariel 5000
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lido Multi-Joint II
Number of subjects: 41
Study: 7524592

Group type: EXPERIMENTAL
Intervention: aprotinin (total dose 2,000,000 kallikrein inhibiting units)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 2908755

Group type: EXPERIMENTAL
Intervention: Balsalazide (BSZ) 1 g b.d. orally
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sulphasalazine (SASP) 1 g b.d. orally
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Balsalazide (BSZ)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sulphasalazine (SASP)
Number of subjects: 79
Study: 31345088

Group type: EXPERIMENTAL
Intervention: Signposts program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Generic telephone support
Number of subjects: 71
Study: 28460409

Group type: EXPERIMENTAL
Intervention: 10 mg/kg TA
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 15 mg/kg TA
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 224
Study: 27078269

Group type: EXPERIMENTAL
Intervention: Fundamental Movement Skills (FMS) training for DCD group (DCD[exp])
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (DCD[con])
Number of subjects: 84
Study: 24605299

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency assisted turbinoplasty (RF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Microdebrider assisted turbinoplasty (MD)
Number of subjects: 60
Study: 22968854

Group type: EXPERIMENTAL
Intervention: 375 mg fosphenytoin sodium
Number of subjects: 12

Group type: COMPARATOR
Intervention: 250 mg phenytoin sodium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fosphenytoin sodium (375, 563, and 750 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fosphenytoin sodium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phenytoin sodium
Number of subjects: 12